Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for pancreatic cancer: immunotherapy-chemo combo tested in early trial

NCT ID NCT04787991

First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 27 times

Summary

This early-phase trial tested combinations of immunotherapy drugs with standard chemotherapy in 45 people with metastatic pancreatic cancer that had not been treated before. The main goal was to check safety and side effects, while also looking at how well the tumors shrank or were controlled. The study is complete, and results help guide future research for this hard-to-treat cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • M.D. Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Stanford University

    Stanford, California, 94305, United States

  • University of California, Los Angeles

    Los Angeles, California, 90095, United States

  • University of California, San Francisco

    San Francisco, California, 94143, United States

  • University of Pennsylvania, Abramson Cancer Center

    Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.